CeQur Appoints Michael Trautmann, MD Medical Director for Anti-Diabetic Peptides

   CeQur Appoints Michael Trautmann, MD Medical Director for Anti-Diabetic

- Former Lilly Senior Medical Officer Will Lead Program Investigating
Alternative Administration of Peptide Therapies Using CeQur Innovative
Delivery Technology -

PR Newswire

HORW, Switzerland, Dec. 11, 2012

HORW, Switzerland, Dec. 11, 2012 /PRNewswire/ --CeQur SA, a company focused
on the development and commercialization of simple delivery devices for
diabetes, announced the appointment of Michael Trautmann, MD as medical
director for anti-diabetic peptides, effective immediately.

Dr. Trautmann has nearly 30 years of experience treating patients and
conducting research in the fields of diabetes and endocrinology. From 1993 to
2012, he held senior clinical research positions at Lilly Research
Laboratories, with responsibilities that included contributing to the clinical
development of insulin lispro and serving as a senior member of the global
team that developed exenatide, a glucagon-like peptide-1 receptor agonist
(GLP-1) used to treat type 2 diabetes. Most recently, Dr. Trautmann served as
senior medical fellow, Lilly Diabetes Global Medical Team.

"Based on the depth and focus of Michael's experience with diabetes research
and treatment, as well as his extensive experience with insulin and GLP-1, he
is the ideal individual to lead our effort investigating the potential to
administer anti-diabetic peptides with our infusion delivery technology," said
James Peterson, founder and CEO of CeQur. "There is a tremendous need for
simple, discreet, effective, and less-invasive therapy for people with type 2

"We are excited to have recently received CE Mark for PaQ, which means our
technology is now ready to help millions of insulin users. Other peptides may
provide additional opportunities to leverage our technology to help those
struggling with diabetes treatment," Peterson said.

The PaQ Delivery Device is a discreet, wearable device that provides three
days of consistent, basal insulin infusion along with easy, on-demand bolus
delivery. The device consists of a disposable insulin-infuser reservoir
attached to a reusable insulin monitor. PaQ is simple to use, making it easy
to train patients to start and stay on therapy. CeQur is investigating the
potential to adapt this low-cost and accurate delivery technology to deliver
other important diabetes therapies.

In his new role, Dr. Trautmann will guide the qualification process for the
CeQur device as an infuser for GLP-1 and, potentially, other peptides to treat
people with type 2 diabetes. GLP-1 is an initial target area for CeQur due to
the demonstrated need for administration methods that help patients achieve
optimal GLP-1 plasma levels for sustained periods, maximizing efficacy while
minimizing side effects. This balance can be difficult to achieve with
currently available dosing options. Results from early-stage trials using
subcutaneous infusion - such as that provided with CeQur technology - suggest
that it is a potentially viable GLP-1 administration option.

"I'm thrilled to join this stellar team of professionals as they work to
improve diabetes treatment," Trautmann said. "The opportunity to explore how
an alternative delivery method may enable a greater number of patients to
access important anti-diabetic peptide therapies is particularly exciting."

About CeQur SA
CeQur^® is dedicated to developing and commercializing advanced delivery
devices that make it easier for people living with type 2 diabetes to adhere
to therapy and stay in control of their disease. The company is headquartered
in Horw, Switzerland, with operations in Nordborg, Denmark and Marlborough,

CeQur was established in January 2008. The company's lead product candidate is
the PaQ Insulin Delivery Device, a novel, wearable device that provides
freedom from multiple daily injections. More information can be found at

Michele Parisi


Website: http://www.cequrcorp.com
Press spacebar to pause and continue. Press esc to stop.